Chemomab Therapeutics to Present at Upcoming Scientific Conferences
04/19/2023 - 07:00 AM
TEL AVIV, Israel , April 19, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in a number of scientific conferences in April and May.
British Society for Rheumatology Annual Conference – April 24-26, 2023
Date:
April 24, 2023
Time:
9:45am BST
Venue:
Manchester Central Convention Complex, Manchester, UK and virtual
Format:
Oral presentation: CCL24 Serum Concentration Predicts Both Vascular and Fibrotic Complications in Systemic Sclerosis: Rationale for a Biological Target Driven, Basket Trial Across Disease Subsets
Presenter:
Professor Enrico De Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal Diseases, University of Leeds, UK
Information:
https://www.rheumatology.org.uk/events-learning/conferences/annual-conference
EASL Monothematic Conference on Biliary Fibrosis 2023 – May 12-13, 2023
Date:
May 12, 2023
Time:
17:20-17:50 CEST
Venue :
Grand Hotel Baglioni, Florence, Italy
Format:
Poster presentation: Patient proteomic data and mouse model reinforce the proinflammatory role of CCL24 in cholestatic disease
Session:
ePoster session 3 and break
Presenter:
Matt Frankel, MD, Chief Medical Officer, Chemomab
Information:
https://easl.eu/event/biliary-fibrosis-23/
In addition, Chemomab's corporate development team will be in Boston June 5-8, 2023 , participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com .
Contacts:
Investors:
Investors & Media:
Irina Koffler
Barbara Lindheim
LifeSci Advisors, LLC
Chemomab Therapeutics
Phone: +1 (917) 734-7387
Consulting Vice President, Investor & Public Relations
ir@chemomab.com
Strategic Communications
barbara.lindheim@chemomab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301801509.html
SOURCE Chemomab Therapeutics, Ltd.
Chemomab Therapeutics Ltd
CMMB Rankings
N/A Ranked by Stock Gains
CMMB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About CMMB
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).